Matthijsen Robert A, de Winther Menno P J, Kuipers Dian, van der Made Ingeborg, Weber Christian, Herias M Veronica, Gijbels Marion J J, Buurman Wim A
Department of Surgery, Maastricht University Medical Centre and School for Nutrition and Metabolism, Maastricht, Netherlands.
Circulation. 2009 Apr 28;119(16):2188-95. doi: 10.1161/CIRCULATIONAHA.108.830661. Epub 2009 Apr 20.
With consideration of the central role of the innate immune system in atherogenesis and mannose-binding lectin (MBL) as an innate regulator of immunity, the role of MBL in experimental and human atherosclerosis was assessed.
With the use of immunohistochemistry and polymerase chain reaction, deposition and gene expression of MBL-A and -C were assessed in murine atherosclerosis from mice deficient for the low-density lipoprotein receptor (LDLR(-/-)) after 10 or 18 weeks of high-fat feeding. MBL was present and was produced in 10-week-old lesions, whereas deposition and gene expression were minimal after 18 weeks of high-fat feeding and absent in healthy vasculature. Interestingly, deposition of MBL-A and -C differed: MBL-A predominantly localized in upper medial layers, whereas MBL-C was found in and around intimal macrophages. To further study the role of local MBL production by monocytic cells in atherosclerosis, LDLR(-/-) mice with MBL-A and -C(-/-) monocytic cells were construed by bone marrow transplantation. Mice carrying MBL-A and -C double deficient macrophages had increased (30%) atherosclerotic lesions compared with wild-type controls (P=0.015) after 10 weeks of high-fat diet. Subsequently, analysis of MBL deposition and gene expression in advanced human atherosclerotic lesions revealed the presence of MBL protein in ruptured but not stable atherosclerotic lesions. Putatively in agreement with murine data, no MBL gene expression could be detected in advanced human atherosclerotic lesions.
These results are the first to show that MBL is abundantly present and locally produced during early atherogenesis. Local MBL expression, by myeloid cells, is shown to critically control development of atherosclerotic lesions.
鉴于先天免疫系统在动脉粥样硬化形成中的核心作用以及甘露糖结合凝集素(MBL)作为免疫的先天调节因子,对MBL在实验性和人类动脉粥样硬化中的作用进行了评估。
利用免疫组织化学和聚合酶链反应,在高脂喂养10周或18周后,对低密度脂蛋白受体缺陷(LDLR(-/-))小鼠的实验性动脉粥样硬化中MBL-A和-C的沉积及基因表达进行了评估。MBL在10周龄的病变中存在且产生,而在高脂喂养18周后沉积和基因表达极少,在健康血管中不存在。有趣的是,MBL-A和-C的沉积有所不同:MBL-A主要定位于中层上部,而MBL-C在内膜巨噬细胞内及周围发现。为进一步研究单核细胞局部产生的MBL在动脉粥样硬化中的作用,通过骨髓移植构建了具有MBL-A和-C(-/-)单核细胞的LDLR(-/-)小鼠。在高脂饮食10周后,携带MBL-A和-C双缺陷巨噬细胞的小鼠与野生型对照相比,动脉粥样硬化病变增加了30%(P=0.015)。随后,对晚期人类动脉粥样硬化病变中MBL的沉积和基因表达分析显示,在破裂而非稳定的动脉粥样硬化病变中存在MBL蛋白。推测与小鼠数据一致,在晚期人类动脉粥样硬化病变中未检测到MBL基因表达。
这些结果首次表明,MBL在早期动脉粥样硬化形成过程中大量存在且局部产生。髓系细胞局部表达的MBL对动脉粥样硬化病变的发展起关键控制作用。